Priority review for MSD’s Keytruda for Merkel cell carcinoma
US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Read More
